A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 640
- Registration Number
- NCT05460000
- Locations
- 🇦🇹
Universitätsklinik Innsbruck, Innsbruck, Austria
🇩🇪Universitätsklinikum Aachen, Aachen, Germany
🇩🇪DRK-Kliniken Berlin-Köpenick, Berlin, Germany
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 33
- Registration Number
- NCT04575961
- Locations
- 🇩🇪
Kliniken Essen Mitte, Essen, Germany
🇩🇪Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 42
- Registration Number
- NCT04227522
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
🇩🇪Städtisches Klinikum Dessau, Dessau, Germany
🇩🇪Städtisches Krankenhaus Kiel, Kiel, Germany
Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 1191
- Registration Number
- NCT03503799
- Locations
- 🇩🇪
ANregiomed Ansbach, Ansbach, Germany
🇩🇪Krankenhaus St. Marienstift, Magdeburg, Germany
🇩🇪Frauenklinik der Technischen Universität München, München, Bayern, Germany
Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2023-11-21
- Target Recruit Count
- 89
- Registration Number
- NCT03164980
- Locations
- 🇩🇪
Studien GbR Braunschweig, Braunschweig, Germany
🇩🇪Universitätsfrauenklinik Leipzig, Leipzig, Germany
🇩🇪Sankt Gertrauden-Krankenhaus, Berlin, Germany
Pazopanib Vs. Pazopanib Plus Gemcitabine
- Conditions
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 58
- Registration Number
- NCT02203760
- Locations
- 🇩🇪
Universitätsklinikum Bonn, Bonn, Germany
🇩🇪Helios Klinikum Berlin-Buch, Klinik für Onkologie und Paliativmedizin, Berlin, Germany
🇩🇪Helios Klinikum Bad Saarow, Hämatologie, Onkologie und Palliativmedizin, Sarkomzentrum, Bad Saarow, Germany
Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes
- Conditions
- Interventions
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2010-07-29
- Target Recruit Count
- 1034
- Registration Number
- NCT00668616
- Locations
- 🇩🇪
Oskar-Ziethen-Krankenhaus, Berlin, Germany
Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2016-09-22
- Target Recruit Count
- 550
- Registration Number
- NCT00437307
- Locations
- 🇩🇪
Charité Campus Virchow Klinikum, Berlin, Germany
Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy
- Conditions
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2006-04-11
- Target Recruit Count
- 450
- Registration Number
- NCT00312988
- Locations
- 🇩🇪
Charité Campus Virchow-Klinikum, Berlin, Germany
Preference Study With Elderly Patients Recurrent Ovarian Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-06-03
- Target Recruit Count
- 123
- Registration Number
- NCT00170690
- Locations
- 🇩🇪
Charité Campus Virchow-Klinikum, Berlin, Germany